Physician profile
John B Addo
NPI 1922063189
$6,285.42
in general payments reported to CMS, 2019-2025
46 companies · $816 in 2025
The $816 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,112 · 2020: $808 · 2021: $1,507 · 2022: $882 · 2023: $585 · 2024: $576 · 2025: $816.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,977.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,977.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $892.84 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $886.78 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Sanofi-Aventis U.S. LLC | $613.24 | 2019-2023 | |
| Glaxosmithkline, LLC. | $417.33 | 2019-2025 | Trelegy Ellipta, Shingrix |
| Lilly USA, LLC | $350.14 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $281.25 | 2019-2025 | Evenity, Repatha, Otezla |
| Pfizer INC. | $264.46 | 2019-2025 | |
| Abbvie INC. | $236.61 | 2021-2025 | Ubrelvy |
| Amarin Pharma, INC. | $225.27 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $189.30 | 2019-2023 | Verquvo, Steglujan, Steglatro |
| Novartis Pharmaceuticals Corporation | $185.54 | 2019-2024 | |
| Abbott Laboratories | $146.10 | 2019-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $144.89 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $137.85 | 2019-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $131.82 | 2019-2024 | Jardiance |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Addo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.